SCHEMBL3078427

SCHEMBL3078427

O=C(c1ccc(-c2nc3c(I)c(Cl)cnc3[nH]2)cc1)N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 7/20 0.48
JAK2 O60674 2/20 0.48
RIPK1 Q13546 1/20 0.48
PHGDH O43175 1/20 0.46
CDK1 P06493 1/20 0.44
CDK2 P24941 1/20 0.44
CDK9 P50750 1/20 0.44
PKM P14618 1/20 0.44
PIK3CA P42336 1/20 0.43
MTOR P42345 1/20 0.43
PIK3CG P48736 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ATR Q13535 1/20 0.43
AKR1C3 P42330 1/20 0.43
HPGD P15428 3/20 0.42
PLK4 O00444 1/20 0.42
MAP4K4 O95819 1/20 0.42
ROS1 P08922 1/20 0.42
FGFR1 P11362 1/20 0.42
FLT1 P17948 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4748880 0.88 RIPK1 (0.48) RIPK1PIK3CAMTORPIK3CGATR
SCHEMBL3096597 0.88 ATR (0.49) JAK2RIPK1CDK1CDK2CDK9
SCHEMBL3084428 0.88 RIPK1 (0.48) LRRK2JAK2RIPK1PHGDHCDK1
SCHEMBL4908920 0.84 RIPK1 (0.55) LRRK2JAK2RIPK1PHGDHCDK1
SCHEMBL3087718 0.80 PARP1 (0.43) HPGD
SCHEMBL3087712 0.80 PARP1 (0.49) JAK2CDK1CDK2CDK9
SCHEMBL17645897 0.78 RIPK1 (0.55) LRRK2RIPK1PHGDHCDK1CDK2
SCHEMBL3083372 0.77 RHEB (0.54) PKMSMN1; SMN2HPGD
SCHEMBL14041306 0.76 RIPK1 (0.48) RIPK1CDK1CDK2PIK3CAMTOR
SCHEMBL14041305 0.76 RIPK1 (0.48) RIPK1PIK3CAMTORPIK3CGATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234593-A1 Imidazo[4,5-B]Pyridine-7-Carboxamides 704 ASTRAZENECA AB (SE) 2010-09-16 US claimed
US-20100234593-A1 Imidazo[4,5-B]Pyridine-7-Carboxamides 704 ASTRAZENECA AB (SE) 2010-09-16 US disclosed
US-20100234593-A1 Imidazo[4,5-B]Pyridine-7-Carboxamides 704 ASTRAZENECA AB (SE) 2010-09-16 US disclosed
US-20100234593-A1 Imidazo[4,5-B]Pyridine-7-Carboxamides 704 ASTRAZENECA AB (SE) 2010-09-16 US disclosed
WO-2008121063-A1 NEW IMIDAZO[ 4,5-B]PYRIDINE-7-CARBOXAMIDES 704 ASTRAZENECA AB (SE) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234593-A1 Imidazo[4,5-B]Pyridine-7-Carboxamides 704 HDAC4, HDAC7, BRD4 LRRK2 3973/4885JAK2 123/4885RIPK1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.